Dual immunotherapy: Experience in Mesothelioma

Dr. Toby Talbot, Royal Cornwall Hospital, UK

Dr. Talbot discusses a 82 year old male patient with epithelioid mesothelioma. He discusses his approach to managing this patient, including efficacy parameters, as well as management of immune related hepatitis which was experienced by the patient.

Dual immunotherapy: Experience in mNSCLC

Dr. Linardou Metropolitan Hospital, Athens, Greece

Dr. Linardou discusses a 74 year old female patient with metastatic adenocarcinoma of the lung. She discusses her approach to managing this patient, including efficacy parameters in both lung and brain, as well as management of hypophysitis which was experienced by the patient.

Meet-the-Expert:

Interactive Panel Discussion

Topics discussed by dr Talbot and dr Linardou included rationale and patient selection for dual immunotherapy vs monotherapy in NSCLC, duration of treatment and stopping after two years in NSCLC & MPM, strategies for discontinuing treatment due to irAEs, rechallenging in NSCLC, second-line treatment options, and patient education with regards to safety.